GLP−1 receptor agonists (including liraglutide and semaglutide) improve neuronal insulin resistance by enhancing insulin-sensitive glucose utilization and inhibiting yeast fluke driven by hyperglycemia (Drucker et al., 2017). Here, INS is linked to Hyperglycemia.